The Government of Brazil announced this Monday that it obtained “positive results” in an “early” treatment against COVID-19, through the application of the antiparasitic nitazoxanida in patients who have the disease in its initial phase.
The announcement was made in an act led by the country’s president, Jair Bolsonaro, who recalled that at the time he defended the treatment of COVID-19 with hydroxychloroquine, which still sows doubts in the scientific community, and asked do not distrust now the possibilities that nitazoxanide can offer.
The results were presented by doctor Patricia Rocco, study coordinator and specialist in lung diseases with more than 30 years of experience, who said that the treatment showed that nitazoxanide was “effective” in reducing viral load of patients who had already contracted COVID-19.
Rocco explained that, between June and August, 1,575 volunteers who had coronavirus in an initial phase were treated with this drug and that in 95% of cases there was a reduction in viral load “without damage to lung cells” or other collateral problems.
The doctor indicated that the patients received 500 milligrams of nitazoxanide three times a day for five days, but he refrained from offering further details about the treatment because the study results have been sent to an international “major scientific journal” for collation.
The Minister of Science and Technology, Marcos Pontes, said that “science is the only weapon that exists to fight the virus “and appreciated the effort made by the promoters of the study.
“We have a proven drug that is capable of reducing the viral load of the coronavirus, thereby reduces contagion and it reduces the possibility that the disease progresses with more force in the patient, “said Pontes.
“It is a low-cost drug, it works to reduce viral load, but it is not preventive, so it cannot be used before “a person contracts COVID-19, Pontes said.